Corporate Banner
Satellite Banner
Metabolomics & Lipidomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Biomarkers Found for Major Depressive Disorder

Published: Thursday, May 23, 2013
Last Updated: Thursday, May 23, 2013
Bookmark and Share
New research highlights biological and genetic markers associated with improved response to adjunctive L-Methylfolate in management of depression.

New research that finds links between biological and genetic markers and improved response to L-methylfolate as an augmentation therapy for major depressive disorder (MDD) is the focus of three presentations at this year’s American Psychiatric Association (APA) and Society of Biological Psychiatry (SOBP) annual meetings.

MDD can include certain metabolic conditions associated with poor response to Selective Serotonin Reuptake Inhibitors (SSRI). A study recently published in the American Journal of Psychiatry (December 2012) examined L-methylfolate 15mg as an adjunct to SSRIs compared to adjunctive placebo. Co-primary endpoints included response (50% reduction) and degree of reduction in depressive symptoms as measured by the Hamilton Depression Rating Scale (HDRS). Secondary and exploratory endpoints included treatment effect in patients stratified by genotypes and other biomarkers including obesity.

Two presentations at the SOBP annual meeting on May 16, and one at the APA annual meeting on May 22, presented data from this published study. 75 outpatients inadequately responding to an SSRI were enrolled in a 60-day study, divided into two, 30-day evaluation periods. Patients were randomized to receive L-methylfolate 15mg + SSRI for 60 days; placebo + SSRI for 30 days followed by L-methylfolate 15mg + SSRI for 30 days; or placebo + SSRI for 60 days. The SSRI doses remained constant during the double-blind phase of the study. Pooled 30 day results demonstrated significantly greater benefits in all-comers with adjunctive L-methylfolate 15mg + SSRI versus placebo + SSRI (continued SSRI monotherapy) according to Sequential Parallel Comparison Design (SPCD). Secondary genomic and biomarker endpoints were evaluated to determine if there was a difference in clinical response to adjunctive L-methylfolate 15mg in patients stratified by genotypes and obesity.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Altered Metabolism of Four Compounds Drives Glioblastoma Growth
Findings suggest new ways to treat the malignancy, slow its progression and reveal its extent more precisely.
A Metabolic Twist that Drives Cancer Survival
A novel metabolic pathway that helps cancer cells thrive in conditions that are lethal to normal cells has been identified.
Liver-On-Chip Tracks Dynamics of Cellular Function
Hebrew University’s liver-on-chip platform is uniquely able to monitor metabolic changes indicating mitochondrial damage occurring at drug concentrations previously regarded as safe.
Living Off the Fat of the Land
Do cancer cells synthesize the parts for new cells or scavenge them from the environment?
Liver Disease, Obesity Linked
Kanazawa University researchers find similarities in the impeded signalling between central insulin activity and glucose production in the liver for both obese mice and mice that have had the vagus nerve removed.
Decoding Ties Between Vascular Disease, Alzheimer’s
NIH consortium uses big data, team science to uncover complex interplay of factors.
Gene Identified that May Worsen Cancer Outcome
Some patients with breast cancer, lung cancer and leukaemia seem to fare poorly after treatment because of the effects of a particular gene, a new study finds.
‘Big Data’ Drills Down Into Metabolic Details
Rice University bioengineers introduce efficient way to analyze, compare tissue-specific pathways.
New Approach to Curbing Cancer Cell Growth
Using a new approach, scientists at The Scripps Research Institute (TSRI) and collaborating institutions have discovered a novel drug candidate that could be used to treat certain types of breast cancer, lung cancer and melanoma.
New Drug Delivery Method for Pancreatic Cancer
UCLA researchers use nanoparticles to send chemotherapy drug directly to the tumor site, reducing damage to healthy tissues.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!